Japanese pharmaceutical firm GNI Group has announced a definitive agreement to acquire Ayumi Pharmaceutical for ¥44.8 billion (approximately £250 million), in a move that will bolster its presence in specialty therapeutic areas. The all-cash transaction, approved by both boards, is expected to close by the end of the third quarter, subject to regulatory clearance.
Ayumi Pharmaceutical, based in Tokyo, focuses on treatments for respiratory diseases and autoimmune disorders, including a marketed product for idiopathic pulmonary fibrosis. GNI Group, which already has a strong foothold in the Chinese and Japanese markets, said the acquisition will complement its existing pipeline and provide access to Ayumi’s established commercial infrastructure.
The deal comes amid a wave of consolidation in the global pharmaceutical industry, as companies seek to diversify revenue streams and bolster R&D capabilities. For UK investors, the transaction serves as a reminder of the value being placed on specialised drug developers, particularly those with approved products in high-demand areas such as respiratory care and immunology.
Analysts at Jefferies noted that the acquisition price represents a premium of roughly 35 per cent to Ayumi’s 30-day average share price, reflecting the strategic importance of its pipeline. “This is a logical bolt-on for GNI, and we expect to see more such deals as mid-cap pharma firms look to scale up,” they said in a note.
While the FTSE 100 edged up 0.2 per cent on Tuesday to 7,642 points, the broader healthcare sector remained subdued. Shares in UK-listed respiratory drug developers such as Synairgen and Arecor were largely flat, though traders said the deal could reignite interest in the sub-sector. No direct UK-listed companies are involved in the transaction.